



Gallagher

Insurance | Risk Management | Consulting

SUMMER 2021

EMI

Employer Market
Intelligence

EMPLOYER MARKET TRENDS

A private ongoing, multiclient study.

Gallagher Research & Insights, St. Louis, MO 63131

© Gallagher Benefit Services, Inc.

All rights reserved. Published 2021

Printed in the United States of America

This Report is licensed only to the original party licensed by Gallagher Benefit Services, Inc. (respectively the "Licensee" and "Gallagher") and is subject to a binding license agreement between Licensee and Gallagher. Gallagher continues to retain title to and ownership of this Report. All copies and portions of this Report, in any form, belong to Gallagher, which retains all rights not expressly granted. Licensee is entitled to use this Report solely for its own internal business purposes and is prohibited from modifying, translating, or otherwise creating derivative works based on this Report. Licensee is further prohibited from licensing, selling, leasing, distributing, lending or otherwise transferring this Report to any third party. Licensee may not make any copies of Gallagher Reports except for internal distribution purposes as described and agreed to in the license agreement provided that all such copies are reproduced with and incorporate all of Gallagher's protective notices, including this and all copyright notices. Nothing in this Report and/or license agreement applicable thereto constitute a waiver of Gallagher's rights under United States Copyright law or any other law.

This information has been obtained from sources which Gallagher believes to be reliable but we do not guarantee the accuracy or completeness of this information.



Gallagher

Insurance | Risk Management | Consulting

SUMMER 2021

EMI

Employer Market
Intelligence

EMPLOYER MARKET TRENDS

A private ongoing, multiclient study.

Table of Contents

Introduction	6
Employer & Coalition Participant Panel	7
Why Employers?	9
Employer Innovation Examples	11
Executive Summary	13
Employer Segmentation	22
Segmentation Overview	22
Segmentation Results & Placement	26
Employer Segmentation—Manufacturer Implications	30
Pharmacy Benefit Management Trends	31
Pharmacy Management Initiatives	31
Value-based Benefit or Insurance Design (VBBD/VBID) for Pharmacy Benefits	33
Employer Perspectives on Prescription Drug Management	34
Formularies & Exclusion List Modifications	36
Alternative Pharmacy Contracting Models	38
Pharmacy Benefit Management Trends—Summary	41
Pharmacy Benefit Management Trends—Manufacturer Implications	42
Biologics & Biosimilars	43
Specialty Concerns & Management Initiatives	43
Copay Accumulator & Maximizer Programs	47
Biosimilar Familiarity & Benefit Design	51
Biosimilars Impact on Specialty Spend	53
Biologics & Biosimilars—Summary	55
Biologics & Biosimilars—Manufacturer Implications	56
Employee Health & Healthcare Management	57
Data Integration	57
Importance of Managing Diseases & Conditions	59
Impact of COVID-19: Approach to Vaccine & Mental Health	63
Technology & Telehealth	65
Obesity Management	68
Employer Worksite Clinics	70
Employer Worksite Clinic Services	72
Value-Focused Healthcare Management	74
Consumer-Directed Health Plans (CDHPs)	77
Employee Health & Healthcare Management—Summary	81
Employee Health & Healthcare Management—Manufacturer Implications	82

Employer Health Coalitions	83
Employer Health Coalition Overview	83
Coalition Quality & Value Initiatives	86
Disease States of Focus & Member Services	88
Coalition Data Integration	91
Coalition Pharmacy Group Purchasing	93
Coalitions & Copay Accumulator Adjustment & Maximizer Programs	96
Disease State & Manufacturer Support of Interest	98
Employer Health Coalitions—Summary	100
Employer Health Coalitions—Manufacturer Implications	101
APPENDIX	102

List of Figures

Figure 1	Overview of Employer Segments	22
Figure 2	Distribution of Employers by Quadrant	26
Figure 3	Employer Sample by Quadrant	26
Figure 4	Segmentation Placement of Research Participants	27
Figure 5	Segmentation Placement of Research Participants by Plot Point	28
Figure 6	Segmentation Summary	29
Figure 7	Proportion of Employers Increasing Employee Cost Share	32
Figure 8	Current and Planned Pharmacy Management Initiatives	32
Figure 9	Participation in a Group Rx Purchasing Collective: 2019 to 2021	32
Figure 10	Employers with Value-Based Benefit/Insurance Design (VBBD/VBID) for Pharmacy Benefits	33
Figure 11	Employer Approach to VBBD/VBID for Pharmacy Benefits	33
Figure 12	Employer Perspectives on PBM's National Formulary & Exclusion Lists	35
Figure 13	Degree of Formulary Restriction in Terms of Access & Coverage of Medications	35
Figure 14	Resources for Identification of Low-Value vs. High-Value Medications and Services	35
Figure 15	Employer Approach to the National Prescription Drug List (PDL)	37
Figure 16	PBM Action When Employer Modifies Standard Prescription Drug List	37
Figure 17	Employers' Approach to Coverage of Drugs on their PBM's (or Health Plan's) Exclusion List	37
Figure 18	Description of Alternative Rx Contracting Agreements	40
Figure 19	Current & Future Use of Alternative Rx Contracting & Purchasing Models	40
Figure 20	Concerns Pertaining to Biologics/Specialty Rx	45
Figure 21	Initiatives to Manage Cost & Utilization of Biologics	45
Figure 22	Most Effective Employer Initiatives for Managing Cost of Biologics/Specialty Rx	46
Figure 23	Disease States for Which Employers Use a Biologics Preferred Drug List	46
Figure 24	Utilization of Copay Accumulator Adjustment Programs	48
Figure 25	Drug Class for Which Copay Accumulator Adjustment Program is Applied	49
Figure 26	Impact of CAAPs on Outcomes	49
Figure 27	Reasons for Not Implementing Copay Accumulator Adjustment Programs	49
Figure 28	Utilization of Copay Maximizer Programs	50
Figure 29	3-Year Trend: Employer Use of Copay Accumulator Adjustment Program (CAAP) & Copay Maximizers	50
Figure 30	Employer Familiarity with Biosimilars: 2019-2021	52
Figure 31	Top Sources for Biosimilar Information and Education, including Cost & Approvals/Pipeline	52
Figure 32	Benefits Management Approaches in Place for Biosimilars	52
Figure 33	Expected Impact of Biosimilars on Total Specialty Drug Spend: 2017-2026	54
Figure 34	Greatest Barriers to Achieving Cost Savings with Biosimilars	54
Figure 35	Degree of Data Integration for Planning, Measurement and Management of Medical & Pharmacy Benefit Decision Making	58
Figure 36	Employer Approach to Data Integration	58
Figure 37	Importance of Managing Disease States or Conditions to Employers	60
Figure 38	Top Disease States or Conditions Impacting Employee Productivity	62

Figure 39	Approach to COVID-19 Vaccine	64
Figure 40	COVID-19 Impact on Employers' Focus on Mental Health	64
Figure 41	Employer Expansion of Mental/Behavioral Health within the Last 12 Months	64
Figure 42	Technology-Driven Healthcare Coverage Added in the Last 12 Months	66
Figure 43	Impact of COVID-19 on Telehealth Utilization	66
Figure 44	Employer Initiatives to Manage Obesity	69
Figure 45	Coverage of Branded Weight Loss Medications	69
Figure 46	Employer Worksite Health Clinics	71
Figure 47	Party Responsible for Running Worksite Clinic	71
Figure 48	Worksite Pharmacy Offerings & Services	71
Figure 49	Services Offered at Worksite Clinics	73
Figure 50	Disease States/Conditions for Which Services, Initiatives, Education or Other Resources are Offered at Worksite Clinics	73
Figure 51	Impact of COVID-19 on Worksite Clinic Services	73
Figure 52	Value-Focused Health Benefit Management	75
Figure 53	Contracting Avenues for Value-Focused Initiatives	75
Figure 54	Use of Risk Sharing (Upside and/or Downside) in Value-Focused Contracts	76
Figure 55	Pharmacy Costs Included in Risk Sharing and/or Bundled Payment	76
Figure 56	Employers Offering CDHPs	78
Figure 57	Employer Approach to CDHP Offerings (2016 to 2021)	78
Figure 58	Percentage of Total Covered Lives Enrolled in CDHPs	78
Figure 59	Use of HSA as Primary Healthcare Account Linked with CDHPs	80
Figure 60	CDHP-HSA Rx Coverage	80
Figure 61	Core Coalition Functions to Improve Local/Regional Healthcare	84
Figure 62	Guidelines for Coalition Tiers	84
Figure 63	Coalition Targets by Tier	85
Figure 64	Trends Gaining Traction in Coalitions' Local Healthcare Markets in 2021	87
Figure 65	Coalition Provision of Healthcare Quality and Cost Data, Tools and Information to Employer & Community Stakeholders	87
Figure 66	Value-Based Initiatives Actively Supported by Coalitions	87
Figure 67	Importance of Disease States or Conditions to Coalitions	89
Figure 68	Coalition Services Offered to Employer Members	90
Figure 69	COVID-19 Resources Coalitions Provide to their Employer Members	90
Figure 70	Coalitions with a Data Warehouse to Collect, Integrate and/or Benchmark Employer Member Benefits Data	92
Figure 71	Coalition Access to Regional/Community-level Health Claims or Population Health Database	92
Figure 72	Elements included in Data Warehouse	92
Figure 73	Coalitions Offering Group Pharmacy Benefit Purchasing	94
Figure 74	Coalition Rx Group Purchasing Snapshot	95
Figure 75	Use of Alternative Rx Contracting Models Among Group Purchasing Coalitions	95

Figure 76	Coalition Perspectives on Copay Accumulator Adjustment Programs	97
Figure 77	Likelihood of Coalitions to Recommend Copay Accumulator Adjustment & Maximizer Programs	97
Figure 78	Top Coalition Disease States of Interest for Receiving Information and Support from Manufacturers	99
Figure 79	Coalition Interest in Manufacturer Support by Type	99

List of Appendix Figures

Figure A1	Breakdown of Research Participants	104
Figure A2	Segmentation Placement of Research Participants by Company Name.	105
Figure A3	Employers' Health Benefits Insurance Strategies	106
Figure A4	Insurance Fee Comparison	106
Figure A5	Employer Research Participants	107
Figure A6	Coalition Research Participants	108

EMI 2021

Employer Market Trends Report

Introduction

Gallagher Research & Insights' seventeenth annual *Employer Market Trends Report* tracks the influence of jumbo employers as healthcare purchasers and studies their role in driving healthcare innovation. As part of the Employer Market Intelligence (EMI) Service, this report examines topics that influence employer benefit design and decision making with a focus on pharmacy benefit management and its impact on biopharma manufacturers.

This primary research was collected via an online survey of benefits decision makers at 98 jumbo employer organizations (5,000+ employees) and leaders of 30 employer health coalitions. Insights were also collected from 12 in-depth interviews with survey respondents. Additional details on the research panel can be found on pages 7-8.

This report is leveraged by biopharma, digital health and diagnostics companies to better understand the employer market and form a strategic approach to drive change and activation among large employers. Each section covers detailed data findings and related trends, verbatims that give a first-hand perspective into employer and coalition viewpoints, and a set of manufacturer implications.

NEW TOPICS IN THE 2021 TRENDS REPORT:

Jumbo Employers:

- Features on innovation in the employer arena: Amazon Care, Employer Health Innovation Roundtable (EHIR) and Health Transformation Alliance (HTA)
- Degree of data integration (*current and planned*)
- Approach to data integration (*internal, health vendor, advisor, data warehouse*)
- Disease additions: Chronic Kidney Disease, HIV
- Impact of COVID-19:
 - Focus on mental health and channels for new or expanded mental or behavioral health offerings (*HP, EAP, behavioral health vendor, onsite clinic*)
 - Telehealth utilization
 - Approach to vaccine
 - COVID-related impact on services offered at worksite clinics (*anti-body testing, increase in utilization, etc.*)

Employer Health Coalitions:


- Access to a database of health claims, population health and/or social determinants of health
- Plans to add data elements to a data warehouse in the next 2 years
- Group pharmacy purchasing coalitions' approach to PBM standard formulary/drug list
- Coalition vaccination group purchasing (*influenza, travel, COVID-19, etc.*)
- COVID-19 resources provided to employer members
- Disease additions: Chronic Kidney Disease, HIV
- Propensity to recommend Copay Accumulator Adjustment & Copay Maximizer Programs to employer members

Contact Sarah Daley at sarah_daley@ajg.com for questions about this report and the EMI Service, or to set up a presentation of findings.


Employer Participant Panel

98 SURVEYS | 8 INTERVIEWS | 5.2 MILLION COVERED U.S. LIVES

PARTICIPANTS BY NUMBER OF U.S. EMPLOYEES



INDUSTRY




- 3% Energy
- 2% Construction
- 2% Public Entity
- 2% Technology
- 2% Union
- 5% Other*

*Other includes: Agriculture, Communications, Hospitality/Entertainment, Religious Inst.


EMPLOYER RESPONDENT ORGANIZATIONAL POSITION



GEOGRAPHICAL BREAKDOWN OF EMPLOYER HEADQUARTERS




PERCENT OF ACTIVE EMPLOYEES IN A UNION




Coalition Participant Panel

30 SURVEYS | 4 INTERVIEWS | 37.8 MILLION MEMBER LIVES



COALITION GROUP BENEFIT PURCHASING




COALITION RESPONDENT ORGANIZATIONAL POSITION



SCOPE OF COALITION MEMBERSHIP & ACTIVITY



GEOGRAPHICAL BREAKDOWN OF COALITION LOCATIONS



See Appendix Figures A5 and A6 for a full list of employer and coalition participants.

Employer Segmentation

SEGMENTATION OVERVIEW


Gallagher Research & Insights' Proprietary Segmentation Model is a Tool to Better Understand and Predict Employer Behavior

GRI's Segmentation model allows manufacturers to invest their targeting, engagement and collaboration efforts in employers who are most likely to take action and have influence in the broader market. In practice, manufacturers utilize the model in a variety of ways, ranging from evaluating the employer market to informing strategy development to targeting employers for engagement through non-personal promotion.

The model emphasizes two central dimensions of employer behavior:

- Willingness to take action to implement solutions (x-axis), and
- Level of strategy in decision making (y-axis).

Figure 1: Overview of Employer Segments



The Most Activated Employers (x-axis)...

- Have independent processes for evaluating vendor partner recommendations
- Are less reliant on benchmarking data, and are among the first to try a new approach
- Have a record of pushing back against recommendations made by vendors (health plan or PBM)

The Most Strategic Employers (y-axis)...

- Have a 3+ year plan for managing health benefits
- Collect and use data from multiple programs (medical, pharmacy, wellness, disability, absence) when planning and evaluating benefit decisions
- Make evidence-based decisions

Many Employers Reduce Employee Cost Share for Specialty or Branded Medications through their Value-Based Insurance Design

Value-based insurance design for pharmacy management is projected to gain substantial traction with employers in the next two years (+20% percentage points by 2023). However, due to the ongoing distraction of the COVID-19 crisis, adoption of new initiatives may have a longer runway. For the time being, 35% of employers currently have VBID in place, a demonstration of measured but steady growth from 24% in 2017.

Most commonly, employers with VBID for pharmacy benefits move generic medications to the lowest tier (50%, +7 percentage points from 2020), and in some cases make them free (29%, -11 percentage points from 2020). Many employers also place specialty (38%) or branded (32%) medications on a reduced tier that lowers qualifying employees' copay/coinsurance amounts. VBID usually includes a component of employee action such as ongoing interaction with a care manager or participation in a wellness program.

“We have a \$0 copay for insulin and diabetes supplies. Participants are responsible for 100% of cost above generic or preferred brand name.”

– Director of Benefits, Employer

Figure 10: Employers with Value-Based Benefit/Insurance Design (VBBD/VBID) for Pharmacy Benefits





Figure 11: Employer Approach to VBBD/VBID for Pharmacy Benefits (among employers with VBBD/VBID for Rx in place)



Employers Play a Support Role in COVID-19 Vaccination Education and Accessibility, but Largely Avoid Driving Action

Supporting patients' mental and physical health in the current stressful and uncertain environment is paramount, as are questions around the pandemic's effect on benefit design and budgets over the next few years. This section examines how employers are approaching the COVID-19 vaccine and mental health offerings.

As vaccination availability became a reality, most employers (81%) focused on communicating to employees the important role the vaccine plays in overall population health. Over six in ten employers (68%) are bringing the vaccine to the worksite to ease accessibility and convenience. Half of employers are keeping employees informed on eligibility and availability of vaccination access as this is evolving quickly. There is a measure of hesitancy among employers in taking hard and fast measures to incentivize (21%) or require vaccines (16%), as well as to offer paid time off to receive it (15%).

COVID-19 Amplifies Employer Focus on Mental Health, Spotlighting an Important Dimension of Employee Wellbeing

In the wake of COVID-19, the drive to provide quality mental health resources intensified. Ninety-one percent (91%) of respondents report an increase in their attention to mental health within the organization, 46% of which reported a significantly increased focus. Over three-fourths of employers (78%) took action, adding mental/behavioral health offerings. A majority (58%) expanded their offerings through an EAP vendor. Some chose to expand offerings through their health plan (34%), behavioral health vendor (23%) or onsite clinic (11%). Approaches to benefit design surrounding mental health may differ among employers, but many cite positive feedback from employees who have taken advantage of these benefits. Many employers remain committed to communicating availability of mental health resources to employees, aiming to drive utilization and provide support for employees in need.

"We're going to strongly encourage, but not require vaccinations. We have some people who aren't going to be comfortable coming back into the office unless everybody's been vaccinated, but that's not something we're going to tackle."

– SVP Global HR, Employer

"[In light of the pandemic] we reinforced programs that we have in place through our Employee Assistance Program. We adopted flexible work policies. We also put in a program for reduced hours and offered an unpaid leave arrangement for certain individuals. We didn't have a lot of take up on it, but those that did appreciated it. As the pandemic wore on, people got used to the new normal and adjusted."

– Director of Rewards, Employer

"We've definitely improved our communications regarding our mental health benefits, and we've added different services for people leaders, our executive leaders, and our employees around resiliency and managing employees with mental health stress."

– Retirement & Healthcare Leader, Employer

78%
of employers added a mental/behavioral health offering in the last 12 months

Figure 39: Approach to COVID-19 Vaccine




Figure 40: COVID-19 Impact on Employers' Focus on Mental Health





Figure 41: Employer Expansion of Mental/Behavioral Health within the Last 12 Months




Transparency is Top Priority as Coalitions Look to Support Members in Offering Higher Value and Superior Quality Care

Nine in ten coalitions report quality and price transparency initiatives have garnered significant or moderate traction in their local markets. As such, two-thirds (67%) promote both pricing and quality transparency by providing tools and education such as total cost of care calculators.

Greater transparency is a key driver for achieving better value in healthcare purchasing. Actively supporting use of high quality providers (via high performance networks and Centers of Excellence) is surveyed as coalitions' top value-focused initiative (70%). Many employers are taking healthcare quality into their own hands and offering worksite clinics. In fact, 90% of coalitions report increased traction around worksite clinics in their local market.

"We've been able to demonstrate that the value of a coalition is creating transparency. We did a joint replacement report, and we're asking our members, 'Are you thinking about how you might use it with your networks? Have you compared it against your Centers of Excellence for orthopedic surgery?"

– Executive Director, Coalition



Segmentation

Rx Benefits

Health Management

Coalitions

The first alliance of its kind between a national employer organization and a regional coalition, **The Purchaser Business Group on Health (PBGH)** and **The Colorado Purchasing Alliance (TCPA)**, jointly identify centers of excellence and establishes direct provider contracting relationships only with facilities and their associated physicians that meet national quality standards at competitive prices.

- Contract directly with centers of excellence for select condition categories, including orthopedics, pregnancy and mental health
- Physician practices and physician-governed organizations engaged to manage chronic disease more effectively

Source: National and Regional Employer Groups Partner in Colorado to Jointly Contract with High-Quality Health Care Providers, Centers of Excellence > PBGH

The Pandemic Put a Pin in Many Coalitions' Quality and Value-Focused Efforts, but Plans to Resume Activity Are Strong

Traction reported for initiatives across the board was notably subdued last year, with the exception of price transparency. COVID-19-related distractions certainly had an impact, but interviewed coalitions expressed the aim of recapturing employer attention by mid-2021.

"We have found that our members are all consumed, and they have COVID fatigue. Most employers made very few changes in the past year. We pivoted to provide our members with info on what's coming and a heads-up of different things in the marketplace related to the pandemic. We're trying to position ourselves so when they emerge at the end of COVID they'll be able to start thinking about what they're going to do for their strategies and their plan."

– President & CEO, Coalition

As coalitions look ahead and anticipate future offerings, 40% plan to develop systems that measure the total cost of care for specific treatments. If those numbers come to fruition, 67% of coalitions could be measuring total treatment cost for certain conditions by 2023. These efforts could be pivotal to achieving the overarching goal of improved price transparency.

The next largest area of anticipated growth is payment reform to reward providers for delivering greater value (+27 percentage points by 2023). Currently, half of coalitions are actively promoting these changes by encouraging bundled payments and/or provider agreements that include shared savings for delivering certain outcomes.



Gallagher

Insurance | Risk Management | Consulting

12444 Powerscourt Drive, Suite 500
St. Louis, MO 63131-3612

o 314.968.0011

f 314.968.1199

www.benfieldresearch.com